Valuation Metrics and Market Context
As of 1 Feb 2026, Morepen Laboratories trades at ₹36.37, up 3.59% from the previous close of ₹35.11. The stock’s 52-week range spans ₹33.47 to ₹70.40, indicating significant volatility over the past year. The company’s current P/E ratio stands at 26.42, a figure that has shifted its valuation grade from attractive to fair. This contrasts with several peers in the Pharmaceuticals & Biotechnology sector, many of which maintain very expensive or expensive valuations. For instance, Gland Pharma and J B Chemicals & Pharmaceuticals exhibit P/E ratios of 34.72 and 39.54 respectively, while Wockhardt’s P/E ratio is an outlier at 304.35, reflecting unique company-specific factors.
Morepen’s price-to-book value of 1.67 also supports this fair valuation stance, positioning it below the sector’s more richly valued companies. The enterprise value to EBITDA (EV/EBITDA) ratio of 15.54 further corroborates this moderate valuation, especially when compared to peers like Emcure Pharma at 17.44 and Pfizer at 22.35. These metrics suggest that while Morepen is no longer considered undervalued, it remains reasonably priced relative to its earnings and book value.
Financial Performance and Returns Analysis
Examining Morepen’s financial returns reveals a mixed picture. The company’s return on capital employed (ROCE) is 7.19%, and return on equity (ROE) is 6.31%, both modest figures that may contribute to the tempered valuation outlook. Dividend yield remains low at 0.55%, indicating limited income generation for shareholders in the near term.
From a returns perspective, Morepen has underperformed the benchmark Sensex over multiple time horizons. Year-to-date, the stock has declined by 11.44%, compared to a Sensex drop of 3.46%. Over the past year, Morepen’s share price has fallen sharply by 41.95%, while the Sensex gained 7.18%. Even over five and ten years, Morepen’s returns of 31.30% and 13.83% lag behind the Sensex’s 77.74% and 230.79% respectively. This underperformance highlights challenges in sustaining growth and investor confidence amid sector headwinds.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Comparative Valuation Within the Sector
Morepen’s valuation contrasts sharply with several key competitors. Gland Pharma and J B Chemicals & Pharmaceuticals are rated very expensive with P/E ratios exceeding 34 and EV/EBITDA multiples above 18 and 25 respectively. AstraZeneca Pharmaceuticals and Pfizer also command very high valuations, with P/E ratios of 92.3 and 29.56, and EV/EBITDA multiples of 65.91 and 22.35 respectively. These elevated multiples reflect strong growth prospects, robust earnings, or premium brand positioning in global markets.
In comparison, Morepen’s fair valuation grade and moderate multiples suggest a more cautious market stance. The company’s PEG ratio remains at zero, indicating either flat or negative earnings growth expectations, which contrasts with peers like Gland Pharma (PEG 1.53) and J B Chemicals (PEG 2.79) that signal growth premium pricing.
Mojo Score and Rating Update
MarketsMOJO’s proprietary scoring system assigns Morepen a Mojo Score of 26.0, categorising it as a Strong Sell. This represents a downgrade from the previous Sell rating as of 24 Nov 2025. The downgrade reflects deteriorating fundamentals, valuation shifts, and relative underperformance. The company’s market cap grade remains low at 3, underscoring its mid-cap status and limited scale compared to larger pharmaceutical players.
Investors should note that the downgrade and valuation adjustment come amid a challenging macroeconomic environment for the pharmaceutical sector, including pricing pressures, regulatory scrutiny, and competitive intensity. These factors have weighed on Morepen’s earnings visibility and growth prospects, justifying the more cautious stance.
Holding Morepen Laboratories Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Outlook and Investor Considerations
While Morepen Laboratories’ valuation has moderated to a fair level, the company’s fundamentals and sector positioning warrant careful scrutiny. The modest ROCE and ROE figures suggest limited capital efficiency and shareholder returns, while the low dividend yield offers little income cushion. The stock’s recent price appreciation of 3.59% and weekly return of 6.41% outperform the Sensex’s 0.90% weekly gain, but longer-term returns remain disappointing.
Investors should weigh Morepen’s valuation against its growth prospects and sector risks. The pharmaceutical industry continues to face regulatory challenges and pricing pressures, which may constrain earnings growth. Comparatively, peers with higher valuations often justify their multiples through stronger earnings momentum or global market exposure.
In conclusion, Morepen Laboratories Ltd’s shift from attractive to fair valuation reflects a market reassessment of its earnings potential and risk profile. While the stock may offer value relative to some expensive peers, the strong sell rating and subdued financial metrics counsel caution. Investors seeking exposure to the Pharmaceuticals & Biotechnology sector might consider more robust alternatives with superior growth and return profiles.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
